Nectin-4 Antibody Drug Conjugate Linker Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tumor drugs targeting Nectin-4 have limited efficacy and significant adverse reactions, with a lack of efficient, low-side effect, and affordable options for patients, particularly for cancers like breast and bladder cancer.
Innovation Solution
Development of a humanized anti-Nectin-4 antibody drug conjugate using a novel linker (NH2-PEG3-Val-Cit) for enhanced specificity and internalization, reducing toxicity and improving therapeutic window.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-Nectin-4 antibody drug conjugates are used, then tumor targeting capability is achieved, but significant adverse reactions occur and therapeutic window is narrow
Solution Approach 1:
The patent modifies the linker structure parameters (using NH2-PEG3-Val-Cit instead of conventional linkers) and antibody characteristics to achieve better pharmacokinetic properties and reduced toxicity, thereby widening the therapeutic window while maintaining targeting capability
Solution Approach 2:
The patent introduces a novel linker as an intermediary component between the antibody and cytotoxic drug, which mediates the connection while providing improved stability and reduced off-target effects, leading to fewer adverse reactions
2Power
If conventional antibody drug conjugates are used, then cancer cell killing is achieved, but endocytosis efficiency is limited
Solution Approach 1:
The patent changes the chemical and structural parameters of the linker and antibody conjugate to enhance endocytosis efficiency, enabling faster internalization and more effective drug delivery to cancer cells while maintaining strong killing activity
3Productivity
If current anti-tumor drugs are used, then some tumor inhibition is achieved, but efficacy is limited and toxicity is high
Solution Approach 1:
The patent creates a composite antibody-drug conjugate system with optimized linker and antibody components that work synergistically to achieve enhanced tumor growth inhibition with reduced toxicity, improving the overall therapeutic index
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody drug conjugate demonstrates improved endocytosis, specificity, and reduced toxicity, achieving significant tumor growth inhibition with a wider therapeutic window and fewer adverse reactions compared to existing treatments.
Implementation Method 1
an antibody, and a functional fragment (eg, an antigen-binding fragment) thereof, and an antibody drug conjugate (ADC) that bind to Nectin-4 protein
Implementation Method 2
The antibody drug conjugate demonstrates improved endocytosis
Data Source
AI summary
The present application relates to an anti-Nectin-4 antibody, a drug conjugate and a preparation method and use thereof, which can be effectively used for the treatment and/or prevention of Nectin-4 positive tumors, including cancers, such as breast cancer and bladder cancer.